To include your compound in the COVID-19 Resource Center, submit it here.

Autolus' dual targeting CAR T safe in Phase I/II data for hematological malignancies

Autolus Therapeutics plc (NASDAQ:AUTL) reported preliminary data from a pair of open-label, U.K. Phase I/II trials showing that AUTO3 had a manageable

Read the full 223 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE